Recent Data on Axi-Cel in Lymphoma
Dr Leslie discusses two abstracts on axi-cel recently presented at ASH 2023: a subgroup analysis of ZUMA-7 and the 4-year follow-up from ZUMA-5.
Source: onclive.com
Zuma 7 News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Zuma 7. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Zuma 7 Today - Breaking & Trending Today
Dr Leslie on the Clinical Benefit of Axi-Cel in Elderly Patients With R/R LBCL
Lori A. Leslie, MD, discusses the efficacy and safety of second-line axicabtagene ciloleucel in elderly patients with high-risk, relapsed/refractory large B-cell lymphoma.
Source: onclive.com
Second-Line Axi-Cel Prolongs Survival Over SOC in Elderly Patients With R/R LBCL
The administration of axicabtagene ciloleucel in the second-line setting improved overall survival and progression-free survival vs standard-of-care treatment in patients with relapsed/refractory large B-cell lymphoma who are at least 65 years of age.
Source: onclive.com
Real-World Use of CAR T-Cell Therapy in Patients with Lymphoma
Explore the real-world application of CAR T-cell therapy in lymphoma treatment, from response rates to its role in first-line therapy.
Source: onclive.com
Diffuse Large B-Cell Lymphoma: Moving Novel Therapy to the Frontline Setting
Expert perspectives on recent efforts to move novel therapy from the relapsed/refractory to frontline setting of diffuse large B-cell lymphoma.
Source: onclive.com